Encompass Health Co. (NYSE:EHC) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC cut its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 90.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,041 shares of the company's stock after selling 200,574 shares during the quarter. Guggenheim Capital LLC's holdings in Encompass Health were worth $2,035,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EHC. Charles Schwab Investment Management Inc. boosted its stake in shares of Encompass Health by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock worth $59,544,000 after acquiring an additional 4,345 shares in the last quarter. Central Pacific Bank Trust Division boosted its position in Encompass Health by 15.1% during the fourth quarter. Central Pacific Bank Trust Division now owns 3,195 shares of the company's stock worth $295,000 after purchasing an additional 418 shares in the last quarter. Merit Financial Group LLC acquired a new stake in Encompass Health in the fourth quarter valued at $374,000. MassMutual Private Wealth & Trust FSB increased its position in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after buying an additional 137 shares in the last quarter. Finally, US Bancorp DE raised its stake in shares of Encompass Health by 9.6% during the 4th quarter. US Bancorp DE now owns 1,380 shares of the company's stock worth $127,000 after buying an additional 121 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Stock Up 0.6 %

NYSE EHC traded up $0.59 on Thursday, hitting $101.31. 1,186,911 shares of the stock traded hands, compared to its average volume of 675,627. The company has a market capitalization of $10.20 billion, a P/E ratio of 22.72, a price-to-earnings-growth ratio of 2.31 and a beta of 0.87. The stock has a 50-day moving average of $99.85 and a 200 day moving average of $98.32. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a twelve month low of $81.45 and a twelve month high of $104.55.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. As a group, analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st were given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend was Tuesday, April 1st. Encompass Health's payout ratio is 15.25%.

Insider Buying and Selling

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.10% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on EHC. Barclays increased their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. StockNews.com downgraded Encompass Health from a "buy" rating to a "hold" rating in a research report on Wednesday, April 16th. William Blair reissued an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. KeyCorp upped their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $110.00 target price on shares of Encompass Health in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.